M. E. Garza's  Instablog

M. E. Garza
Send Message
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began... More
My company:
My blog:
Daily Info Feeds and Updates
  • RxNews Recap for Monday 11-25-09 1 comment
    Nov 25, 2009 12:34 PM | about stocks: ZOLL

    Below is a list of the healthcare sector companies that made news in the healthcare sector on Monday, November 21, 2009. This list feature is meant to help investors keep tabs on the sector without having to scour through all the press releases.

    Amarin Corporation plc (NASDAQ: AMRN) announced today that it has sent to its shareholders a Notice of the Annual General Meeting of the Company, which will be held on December 21, 2009 in Dublin, Ireland.

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (NYSE:ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

    Array BioPharma Inc. (Nasdaq: ARRY)
    today announced that its Chief Executive Officer, Robert E. Conway, will speak at the 21st Annual Piper Jaffray Healthcare Conference on December 1 in New York City.

    Catalyst Rx, the pharmacy benefit management (NYSEMKT:PBM) subsidiary of Catalyst Health Solutions, Inc. (NASDAQ: CHSI), announced today that its member-focused Web site, CatalystRx.com, won a Platinum award in the Strategic Health Care Communications’ annual eHealthcare Leadership Awards for Best Interactive Site.

    The clouds of darkness that have been hanging over over CytRx Corporation (NASDAQ:CYTR) may soon be cast aside.

    CDEX Inc. (OTCBB:CEXI) (cdexinc.com) and All Business Machines, Inc. ("ABMI") (abmicorp.com) announce that the ValiMed™ MVS (Medication Validation System) and ID2 Meth Scanner™ product lines by CDEX have been placed on the ABMI GSA Contract Schedule.ValiMed MVS puts a technological safety net between the patient and errors made in the compounding of high risk medications and guards against narcotic diversion.

    MedPro Safety Products, Inc. (OTCBB: MPSP), a pioneer in the development and marketing of passive needlestick injury prevention technology, today reported on the company’s recent progress.

    NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (terrapinn.com/usaflu).

    Neogen Corporation (Nasdaq: NEOG) announced today that Richard T. Crowder, Ph.D., was elected to Neogen's Board of Directors at the company's recentannual meeting of shareholders.

    Origin Agritech Limited (NASDAQ GS: SEED) (“Origin”), a leading technology-focused supplier of crop seeds and agri-biotech research in China, today announced it has received the Bio-safety Certificate from the Ministry of Agriculture as a final approval for commercial approval of the world’s first genetically modified phytase corn.

    Oncolytics Biotech Inc., (TSX:ONC; NASDAQ:ONCY) announced today that it has closed its previously announced US$12,750,00 offering in which a syndicate of underwriters purchased 4,250,000 units of the Company, each unit comprised of one common share and 0.4 of a common share purchase warrant, at a price of US$3.00 per unit.

    As part of its drug pipeline Ohr Pharmaceutical (OTCBB:OHRP) is developing a wet AMD (Macular Degeneration) therapy, based on technology acquired from Genaera Liquidating Trust.

    Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a specialty pharmaceutical company, today announced it has closed its previously announced public offering of 5,500,000 shares of its common stock at a price of $21.00 per share.

    TapImmune, Inc. (OTCBB:TPIV) announced that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report.

    Walgreens (NYSE, NASDAQ: WAG), the nation’s largest drugstore chain and a leading destination for health and wellness services, today announced the re-launch of Walgreens.com (walgreens.com), offering users a variety of new healthy living and product resources, along with expanded yet simplified shopping tools and services.

    Walgreens (NYSE:WAG)(NASDAQ:WAG) today announced the appointment of two new executives. Kathleen Wilson-Thompson has been named senior vice president and chief human resources officer, and Charles V. Greener has been named to the new position of vice president of corporate affairs and communications.

    ZOLL Medical Corporation (NasdaqGS: ZOLL) announced today that the LifeVest® wearable defibrillator was discussed in three separate scientific presentations at the American Heart Association 2009 Science Session in Orlando, Florida last week.

    Stocks: ZOLL
Back To M. E. Garza's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • Rockastocks
    , contributor
    Comments (13) | Send Message
    TPIV had news today bringing some good experience to their team.


    April 11, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has announced that Robert Florkiewicz, Ph.D., has been appointed Senior Director of Molecular Biology & Virology.


    "Bob has a unique combination of skills and experience in the fields of virology and molecular biology that encompasses both the science and intellectual property landscapes" said Mark Reddish, Head of Development. "His career of distinguished scientific work is made all the more valuable by his experience in the area of intellectual property and business development. His combined skills fit into our corporate development plans to expand our IP estate in support of our clinical programs and for leverage in potential partnerships".


    Dr Florkiewicz has experience in both academic and biotechnology environments. Most recently he conducted research on human embryonic stem-cell based therapies at the University of Washington. He was the Director of Cellular and Molecular Biology and co-founder of Ciblex Corporation, a spin-out from his laboratory at the Scripps Institute, San Diego. He was a patent agent at Seed Intellectual Law Group in Seattle and at ID Biomedical where he managed the Company's intellectual property portfolio prior to and through its acquisition by GlaxoSmithKline. He has a Ph.D. in Molecular and Development Biology from the University of Arizona (focusing on the molecular biology of various RNA viruses) and was a postdoctoral fellow at the Salk Institute (focusing on the intracellular trafficking of proteins encoded by vesicular stomatitis virus). As a Research Scientist at Synergen, Inc. he helped establish the viral vector and animal cell expression group, and also discovered novel molecular mechanisms modulating FGF2 gene expression.


    At TapImmune he will lead the team responsible for the design and testing of novel vectors expressing TAP and targeting immunologically modeled peptide antigen arrays associated with immunotherapies for treating cancer and infectious diseases.


    rockastocks was not compensated for this comment on TPIV
    11 Apr 2012, 10:34 AM Reply Like
Full index of posts »
Latest Followers


  • Hearing some interesting developments on the horizon for $NWBO. Did an article on them yesterday. Looks promising. http://bit.ly/NWBOnews
    Jul 12, 2011
  • ($RXPC.PK 3 of 3) If it were bad news, chances are they'd have something by now, since delisting decisions are usually handed down quickly.
    Apr 19, 2011
  • ($RXPC.PK 2 of 3) a listing extension would go until July [when the stock would have to be over $1 to continue being listed on Amex].
    Apr 19, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.